COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More
Clinical Trials Search
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non©\Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature©\driven Analysis
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.
The co-primary objective is to evaluate overall survival (OS) in each of the 2 experimental arms (Arms A and B) to control (Arm C). Secondary Objectives: To evaluate progression-free survival (PFS) per RECIST 1.1 for Arm C versus each of Arms A and B. To evaluate best objective response rates per RECIST 1.1 for Arm C versus each of Arms A and B. To estimate toxicity within each of the treatment arms via the CTCAE criteria. To compare outcomes between Arms A and B. To compare outcomes by treatment arm within subgroups defined by a cutpoint of PD-L1 expression at ¡Ý 50%.
Alimta (Pemetrexed); MK-3475 (Keytruda); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()